We sought to assess the impact of the American College of Cardiology's Guidelines Applied in Practice (GAP) project for acute myocardial infarction (AMI) care, encompassing 33 acute-care hospitals in southeastern Michigan, on rates of mortality in Medicare patients treated in Michigan. BACKGROUND The GAP project increases the use of evidence-based therapies in patients with AMI. It is unknown whether GAP also can reduce the rate of mortality in patients with AMI.
Although the knowledge base for the management of acute myocardial infarction (AMI) has grown substantially in recent decades, numerous studies have suggested that therapies known to be effective are omitted in a surprising percentage of patients (1) (2) (3) (4) (5) . The opportunity to improve AMI care is particularly large for our nation's elderly, in whom the rate of morbidity and mortality is high and the gap between evidence-based guidelines' recommended care and the care actually provided is large (6 -8) .
The American College of Cardiology (ACC), in partnership with the Michigan quality improvement organization (i.e., Michigan Peer Review Organization) and the Greater Detroit Area Health Council, initiated a pilot program in Michigan in 1999 to test the hypothesis that by embedding the key priorities of the national guidelines into AMI care itself, quality could be improved (9, 10) . Three AMI Guidelines Applied in Practice (GAP) projects, involving 33 hospitals, have suggested that rapid-cycle quality improvement could be achieved (11) . Improvement in key indicators was optimized when caregivers adopted a systems approach, driven by routine use of standard, admission orders, a standard discharge contract, and with strong physician, nurse, and administrative leadership (12) . Although the GAP projects have shown improvement in key quality indicators, a favorable impact on patient outcomes is the real goal of GAP. In this study, we examined the impact of guideline-based-standard AMI care on in-hospital, 30-day, and one-year mortality in the Medicare beneficiaries who participated in the three Michigan GAP AMI projects.
METHODS
The GAP projects. After their initial development at the University of Michigan Health System (13), the ACC AMI (GAP) projects included a 10-hospital study in Southeast Michigan in 1999 (10), a 5-hospital project in Flint and Saginaw in 2001 (11) , and an 18-hospital project in Southeast Michigan in 2002 (14) . Each project built upon lessons learned previously. A rapid-cycle quality improvement model was created, emphasizing a collaborative culture of learning, sharing, and problem-solving among hospitals and by designing care processes to assure clinical tool use (11) . The GAP project fosters systems-based care from admission to discharge, incorporating evidence-based tools into practice and targeting patients, physicians, and nurses. The methods used in the ACC GAP projects have been described previously (9 -12,15) . The clinical care tool templates, including standardized orders, a pocket guideline, and a standardized discharge tool, are available elsewhere (16) . The Medicare sample. We examined the impact of GAP on Medicare beneficiaries by studying patients treated in each hospital before and after the implementation of GAP. Baseline samples were created using a 50% random sample with at least 20 cases per hospital of Medicare AMI patients (principal diagnosis code: 410.xx) from patients treated in the year preceding GAP implementation. The post-GAP sample included a 95% to 100% sampling of all Medicare AMI patients in the four months immediately after GAP implementation at each hospital. Hospital records for each patient were copied and forwarded to DynKePRO's Centers for Medicare & Medicaid Services (CMS) Clinical Data Abstraction Center. Each record was screened to ensure that AMI was the principal diagnosis. Then, data regarding patient history, presenting symptoms and signs, rates of comorbidity, diagnostic studies, therapies, outcomes, and use of standard orders and/or the discharge tool were extracted. For quality of care indicators, only ideal cases were included in the denominator. Patients with contraindications were excluded. To assure quality, data were re-abstracted for a random sample of baseline and post-GAP records by the CMS Clinical Data Abstraction Center. Reliability (94%) and accuracy (97%) were high. To assess for 30-day and one-year mortality, Medicare claims were screened using each patient's unique identifier. Statistical methods. We compared patients treated before (baseline) and immediately after the implementation of GAP (post-GAP). Using standard statistics, demographics, presentation variables, rates of comorbidity, diagnostic tests, treatments, and outcomes were analyzed in the two cohorts, including the use of evidence-based therapies and use of AMI standard admission and discharge tools. We examined in-hospital, 30-day, and one-year mortality in baseline compared with post-GAP patients. To assess the potential independent benefit of GAP on mortality, separate multivariate logistic regression models for in-hospital, 30-day, and one-year mortality were developed. Age, troponin levels, and heart rate were included as continuous variables. Each hospital was included in the model as an independent variable to account for practice variation between facilities. Candidate variables included age (continuous), gender, history of MI, previous heart failure, previous chronic obstructive pulmonary disorder, history of stroke, previous percutaneous coronary intervention, left ventricular ejection fraction, chest pain, hematocrit Ͻ30%, heart rate (continuous), anterior MI, inferior MI, atrial fibrillation, percutaneous coronary intervention during the index hospitalization, coronary artery bypass grafting during the index hospitalization, elevated troponin (continuous), in-hospital heart failure, hypertension, elevated creatinine, renal failure, stroke, cardiac arrest, and cardiogenic shock. To assess whether the GAP effect was primarily driven by use of standardized tools, we added their use to the multivariable models to see whether they supplanted the apparent GAP effect. For in-hospital mortality, the independent effect of using standardized orders at admission was analyzed. To assess the influence of clinical care tool use on long-term outcomes, we studied the independent effect of standardized discharge document on 30-day and one-year mortality, after excluding patients with in-hospital death.
RESULTS
Among 2,857 patients studied, 1,368 were in the baseline cohort and 1,489 in the post-GAP cohort. Average age was 76 years. When comparing demographics, previous cardiovascular disease ( Table 4 lists in-hospital complications and mortality data. Mortality in-hospital (10.4% vs. 13.6%; p ϭ 0.017), at 30 days (16.7% vs. 21.6%; p ϭ 0.001), and at one year (33.2% vs. 38.3%; p ϭ 0.04) was significantly lower in the post-GAP patients. Table 5 illustrates the potential independent effect of GAP on hospital, 30-day, and one-year mortality. After adjustment for clinical findings, tests, and treatments, patients cared for post-GAP were less likely to die at 30 days and one year, and there was a trend for better hospital survival as well (Table 5 ).
When we compared the impact of standardized care tools versus the overall impact of GAP, 30-day mortality was significantly less likely among patients receiving the standardized discharge tool (odds ratio 0.52; 95% confidence interval 0.27 to 0.98; p ϭ 0.042; Table 6 ). This variable resulted in elimination of the GAP effect from the model, although GAP drove the use of the standard discharge tool from less than 2% pre-GAP to nearly 31% after GAP. Use of the discharge tool was associated with a significant reduction in one-year mortality (odds ratio 0.53; 95% confidence interval 0.36 to 0.76; p ϭ 0.0006).
DISCUSSION
Previous studies have suggested that adherence to guidelinebased therapeutic goals may have a benefit in lowering acute and long-term outcomes after patients suffer an AMI (17). Because the guidelines reflect a scientific basis for treatment emphasizing strategies that have been studied in large randomized clinical trials (1,3), it makes sense that the actual clinical use of these strategies through guideline implementation would lead to improved patient outcomes. However, most such studies have struggled to demonstrate improvement in process measures, let alone clinical outcomes (18) . Part of this failure has been due to only mild uptake of guideline tools, and much has been attributable to issues of sample size where, unlike large clinical trials, the numbers of patients studied have been modest (13, 19) . Some reports have represented single-center initiatives over the course of long periods of time (19) and have been criticized as reflecting natural diffusion of knowledge into care, not a direct benefit of a labor-intensive guideline implementation effort. Other reports have included voluntary data entry so that assuring similar "before and after" samples was impossible (20) . The failure of guideline implementation efforts to demonstrate improved outcomes has served to fuel nihilism among many care providers regarding the importance of guidelines and their use in practice (21) . The ACC AMI GAP initiatives in Michigan provided a unique opportunity to assess the effect of an active guideline implementation program on outcomes after AMI. We were able to assess the effects of GAP on not only in-hospital quality indicators but also immediate and downstream mortality using data gathered the preceding year as each hospital's control. The results suggest that across 33 hospitals, a rapid-cycle quality improvement effort is associated with a lower 30-day and one-year mortality among Medicare beneficiaries hospitalized for an AMI. The size of this effect appears to be a 21% to 26% reduction in death.
Because our study was not a randomized trial, is it really possible to state that GAP lowered the rate of mortality after an AMI in elderly patients? Although, "before and after" observational studies can "suggest" such effects, uncertainty remains. However, in the case of GAP in Michigan, the accumulated evidence is consistent with this conclusion. First, patients were selected randomly for inclusion and their charts were copied and sent to a data abstraction organization for data extraction. This procedure should mitigate selection bias that can cloud any observational study. Second, the degree of improvement in many of the quality indicators after GAP correlated strongly with increased use of standardized orders and discharge documents. Third, in the GAP pilot project, performance in 11 control hospitals that wanted to participate in GAP but were not selected were compared with 10 GAP hospitals, demonstrating that "wanting to improve" did not achieve the degree of change observed in the participating hospitals (10). Fourth, mortality reduction noted after GAP persisted Are the levels of improvement in mortality apparently owing to the GAP effort really plausible? Could one really expect a 21% to 26% mortality benefit when each of the quality indicators are only improved by an absolute amount from 4% to 10%? We believe the answer is yes. The GAP program emphasizes more than the quality indicators reported here. The system strongly endorses long-term adherence to evidence-based medicines among eligible patients, encourages lifestyle interventions, and documents a follow-up plan at discharge. We have previously shown that achieving multiple pharmacologic and lifestyle targets is not an additive effect, but in fact multiplicative risk reduction in the 6 to 12 months after an acute coronary syndrome or after a peripheral vascular intervention (22, 23) . Also, Fonarow et al. (19) have shown previously a more than 50% lowering of one-year mortality in a study of guideline-based treatment of AMI in an academic medical center. Finally, Lappe et al. (24) recently reported a 21% reduction in one-year mortality after implementing a guideline-based secondary prevention program in patients hospitalized for acute cardiovascular disorder in the mountain west states.
The discharge contract between the hospital and the patient appears to be especially important in achieving the mortality reduction found in this study. The discharge contract ensures that patients are educated about their condition and understand how to take care of themselves after they leave the hospital. It is filled out and explained to the patient in the presence of a physician or a nurse and includes instructions on taking medications, goals for controlling cholesterol levels, smoking-cessation goals, diet and exercise instructions, heart disease education, and instructions to follow-up with the patient's primary care physicians. Both the patient and the provider must sign the contract.
The discharge contract forces processes to take place that may easily be forgotten in the busy environment of a hospital. For the provider to explain everything on the contract to the patient, the provider must go through the process to ensure that all the steps on the contract have been explained. The contract forces providers to either prescribe aspirin, beta-blockers, angiotensin-converting enzyme inhibitors, and cholesterol-lowering agents or document the reason these drugs were not indicated. Similarly, the discharge contract ensures that diet counseling and smokingcessation counseling has occurred, that educational information about heart disease and heart attacks has been provided to patients, and that exercise and cardiac rehabilitation instructions and referrals have been given. The success of the discharge contract lies in its ability to ensure evidencebased processes occur at discharge and the patient is informed about taking care of themselves after they leave the hospital.
Why did GAP work? First, the projects were led by physicians and nurses, with support from the subspecialty's premier professional society, the ACC, and its leaders. Professional leadership and physician engagement are essential to achieving improvement (25) (26) (27) others on AMI quality. Fifth, the intervention focused on the patient-doctor-nurse triangle of care, trying to assure that a short list of key care priorities was emphasized in a consistent way and with systems which supported these priorities during the care itself. Sixth, assuring late benefit of treatments after hospital discharge was enhanced through use of an AMI discharge form. This simple, one-page check-list guarantees that key pharmaceutical and lifestyle goals, their rationale, and their duration of use are understood both by the care provider and the patient. Initiation of secondary prevention treatment, in-hospital, improves the likelihood that patient's will be on treatment 3 to 12 months later (28 -30) . Finally, the willingness of physicians and nurses in Michigan to work together reflects an appreciation that more than 40% of the state's citizens currently die of cardiovascular disease and that by learning from each other, care can improve in each institution (31) . We believe that further improvement is possible. Only 32% of the post-GAP patient charts contained a discharge contract, and Ͻ50% had initial care directed by standardized orders. One GAP hospital has moved from a culture where use of the standardized order sets and discharge document is "encouraged," to a system where it is "guaranteed" for heart failure or acute coronary syndromes. Patients must have orders provided in standard sets, and use of the discharge contract is required. Patients' charts are coded on the floor, in real time, and deficiencies in use of standard care tools and in documentation or adherence to quality indicators are promptly identified and fed back to the care team and the patient. Fundamentally, this approach likens a missed quality of care opportunity to a medical error. This has resulted in adherence to key quality indicators among eligible patients of nearly 100% (20) . Study limitations. The cost-effectiveness of the GAP intervention has not been studied. We do not know whether GAP is more or less cost-effective than other current medical strategies. Regardless of its cost-effectiveness, efforts such as GAP are being adopted because AMI quality indicators are now a key performance measure for hospital accreditation by the Joint Commission for Accreditation of Abbreviations as in Table 5 .
